The US FDA has approved Pfizer’s vaccine Penbraya for ages 10 to 25, offering protection against the five main types of bacteria causing meningitis and blood poisoning. As a two-dose vaccine administered six months apart, it combines elements of Trumenba and Menveo and reduces the current four-dose regimen for full protection. The CDC will discuss recommendations for Penbraya’s use in adolescents and young adults.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
